Showing 621-630 of 9352 results for "".
Noah Worcester 2024: Dr. Adams on Sports Dermatology
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-adams-sports-dermatology/24584/Brian Adams, MD, MPH, summarizes his lecture on treating professional athletes at the 2024 Noah Worcester Dermatological Society meeting.American Academy of Dermatology 2024
Meeting Wrap-Uphttps://practicaldermatology.com/cme/dermatology/meeting-coverage-aad-2024/24461/Practical Dermatology® was at the American Academy of Dermatology 2024 Annual Meeting in San Diego (AAD 2024) reporting on the latest research findings on innovative therapies and insights into managing complex dermatological disorders. From pioneering trials showcasing the efficacy of novel topicalDermWireTV: Novan EPI Acquisition, Champions for Change Gala, Mt. Sinai Alopecia Center
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-novan-epi-acquisition-champions-for-change-gala-mt-sinai-alopecia-center/20070/EPI Health is now a Novan company; the combined company will employ approximately 100 staff. Novan’s lead candidate, berdazimer gel 10.3%, performed well in a phase 3 study for the treatment of molluscum contagiosum. The Skin Cancer Foundation is gearing up for its signature fundraising event: The CElucidating the Inflammatory Cascade May Help to Turn Out the Lights in Psoriasis
https://practicaldermatology.com/topics/psoriasis/elucidating-the-inflammatory-cascade-may-help-to-turn-out-the-lights-in-psoriasis/19943/Understanding the science behind psoriasis pathogenesis has raised the bar in the management of disease. Watch the video to visualize the patient journey, their unmet needs, and aim to set higher standards in the psoriasis landscape.Inside the Latest Edition, June 2021
https://practicaldermatology.com/topics/practice-management/inside-the-latest-edition-june-2021/19959/Go inside our issue on acne and rosacea to get tips on new acne treatments, management of maskne, and strategies to improve your bottom line!Nothing Fishy: The Facts About Alternative Interventions for Skin
https://practicaldermatology.com/topics/psoriasis/nothing-fishy-the-facts-about-alternative-interventions-for-skin/19933/From fish oil to indigo naturalis, several agents may provide modest but reliable benefits that can enhance topical therapy for psoriasis. Similarly, coconut oil and sunflower oil may provide some benefit for eczema. Peter Lio, MD discusses the available data and potential use of these and other ageThread Lifting 4.0
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/thread-lifting-40/19603/Today’s thread lifts bring more to the table than previous iterations. Older threads lifted sagging facial tissue, but now they are absorbable and biostimulatory, which means they can lift and add volume to the face and also aid in scar remodelling, explains Hooman Khorasani, MD.2017 Tax Cuts and Jobs Act: What You Need to Know
https://practicaldermatology.com/topics/practice-management/2017-tax-cuts-and-jobs-act-what-you-need-to-know--vmyiwowa/18348/OJM Group principal Carole Foos, CPA provides an overview of the Tax Cuts and Jobs Act, which was signed in to law at the end of 2017. She discusses key provisions affecting individual physicians and medical practices, and offers advice to consider when planning for 2018 and beyond. Click here to reElections and Markets, Encore and Biofrontera Launches, More
https://practicaldermatology.com/topics/practice-management/dermwiretv-elections-and-markets-encore-and-biofrontera-launches-more/18564/Election years bring market uncertainty, but should you be making any changes to your portfolio now? Financial experts weigh in on why—no matter the results—there's no need for panic. Allergan launches a new campaign, ActuallySheCan, to empower young women. Several new products are now available forAllergan Acquires Vitae, PsA Day, Novan News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-acquires-vitae-psa-day-novan-news/18572/Allergan is acquiring clinical-stage biotechnology company Vitae Pharmaceuticals for $21.00 per share, in cash, for a total transaction value of approximately $639 million. Novan has launched its initial public offering and is now listed on the NASDAQ. Celgene Corporation and the National Psoriasis